Program
rinatabart sesutecan
Its studies are mostly in Ovarian Neoplasms · Fallopian Tube Neoplasms · Endometrial Neoplasms · Gastrointestinal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Genmab.
Furthest: phase 3, since Sep 20, 20249 company-led studies, 9 open or runningNext primary completion: Sep 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genmab | 99 open or running | phase 3since Sep 20, 2024 | Oct 4, 2022 | Sep 2027phase 3 · NCT07604766 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 4, 2022First study: phase 2 study in Fallopian Tube NeoplasmsFirst studyNCT05579366 · 952 planned · United States, China, Japan and more
- Sep 20, 2024Phase 3 study in Ovarian NeoplasmsNCT06619236 · 584 enrolled · United States, Australia, Austria and more
- Sep 9, 2025Phase 3 study in Endometrial NeoplasmsNCT07166094 · 660 planned · United States, Australia, Belgium and more
- Nov 4, 2025Phase 3 study in Ovarian NeoplasmsNCT07225270 · 544 planned · United States, Australia, Austria and more
- Dec 15, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07288177 · 240 planned · United States, Australia, Belgium and more
- Apr 13, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07539311 · 160 planned · United States, Australia, Belgium and more
- Apr 27, 2026Phase 3 study in Ovarian NeoplasmsNCT07564141 · 688 planned · United States, Finland, Japan
- May 18, 2026Phase 3 study in Ovarian NeoplasmsNCT07604766 · 82 planned · China
- Sep 29, 2026Phase 3 study in Ovarian NeoplasmsNCT07859215 · 602 planned
- Nov 4, 2026Primary completion moved from 2027-07 to 2028-12Date moved laterphase 2 · +17 months · NCT05579366
Ahead
- Sep 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT07604766
- Nov 22, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07288177
- Sep 2028Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT07539311
- Oct 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07225270
TargetBeta
FOLR1 →read by rule
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 15 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07859215Ovarian Neoplasms | 3 | Not yet recruiting | Mar 2030 | 602 |
| NCT07604766Ovarian Neoplasms · China | 3 | Recruiting | Sep 2027 | 82 |
| NCT07564141Ovarian Neoplasms · United States, Finland, Japan | 3 | Recruiting | Dec 2029 | 688 |
| NCT07539311Gastrointestinal Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 2028 | 160 |
| NCT07288177Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Recruiting | Nov 22, 2027 | 240 |
| NCT07225270Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Oct 2028 | 544 |
| NCT07166094Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Aug 2029 | 660 |
| NCT06619236Ovarian Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 18, 2026 | 584 |
| NCT05579366Fallopian Tube Neoplasms · United States, China, Japan and more | 2 | Recruiting | Dec 2028 | 952 |
How it is read
Names in the registry
- “Rina-S”, 9 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 5 studies
- Fallopian Tube Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
- Gastrointestinal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.